INTRODUCTION
============

Pregnancy-associated breast cancer (PABC) is breast cancer diagnosed during pregnancy or the first postpartum year \[[@B1][@B2]\]. The incidence of PABC comprises 0.76% to 3.8% of all breast cancer cases \[[@B1]\]. The outcomes of treatment for PABC are generally poor. Bladström et al. \[[@B3]\] have used a Swedish population-based registry to study the survival rates of women with breast cancer who recently gave birth. They found that the 5- and 10-year survival rates were 52.1% and 43.9%, respectively, for patients who had been diagnosed during pregnancy. By contrast, the 5- and 10-year survival rates were 80% and 68.6%, respectively, for patients who had been diagnosed more than 10 years after childbirth \[[@B3]\]. Azim et al. \[[@B4]\] have investigated the prognosis of PABC in a meta-analysis and found that PABC was independently associated with worse overall and progression-free survival rates.

The poor prognosis of PABC might be caused by delays in diagnosis and obstacles to treatment. Diagnostic delay is a common phenomenon in PABC because the normal changes that occur during pregnancy obscure the signs and symptoms of the cancer. Furthermore, the fetus should be protected as much as possible during the treatment of the mother \[[@B1]\]. To improve the outcomes of patients with PABC, understanding its risk factors and tumor characteristics is important. However, this is difficult because the incidence of PABC is low. The Korean Breast Cancer Society (KBCS) Registry database provides a wide variety of information, including whether cases are PABC or non-PABC. We analyzed this nationwide database, which included data collected prospectively more than 15 years ago, to evaluate the clinicopathological characteristics of PABC patients compared with non-PABC patients.

METHODS
=======

Korean Breast Cancer Society Registry
-------------------------------------

Managed by the KBCS, the KBCS Registry is a database that has been prospectively collecting data on breast cancer patients since 1996. A total of 102 general hospitals with at least 400 beds have decided to join this program. The registered factors include age, sex, surgical method, cancer pathologic stage (based on the seventh American Joint Committee on Cancer classification), height, weight, age at menarche, age at menopause, age at first childbirth, lactation history, hormone replacement therapy, family history, PABC or non-PABC, hormone receptor status, human epidermal receptor 2 status, and neoadjuvant or adjuvant treatments \[[@B5][@B6][@B7]\]. The details of the KBCS database have been described in a previous study \[[@B5]\].

Definitions
-----------

PABC was defined as breast cancer diagnosed during pregnancy or within 1 year of childbirth \[[@B1][@B2]\]. Overweight was defined as body mass index (BMI) ≥23.0 kg/m^2^, and obesity was defined as BMI ≥25.0 kg/m^2^, following recommendations for Asian populations \[[@B8]\].

Patients
--------

PABC and non-PABC patients were selected based on information from the KBCS Registry database. Using this database, 344 patients diagnosed with PABC between January 1989 and December 2013 were identified. Patients had to be between 20 and 45 years old to be included in the study. [Figure 1](#F1){ref-type="fig"} shows the flow diagram of patient selection. Non-PABC patients were selected from the KBCS Registry database using a general 1:2 matching method. The matching variables were year of operation, age, and initial stage. We began by matching patients by year of operation. Because different treatment strategies are associated with different operation periods, non-PABC patients were selected such that they underwent operations during the same year as did the PABC patients. Age and initial stage are typical prognostic factors. Therefore, we also matched patients in the two groups on these variables, to analyze the differences that remained in other characteristics. The matched patients were defined to have undergone their operations during the same year, to be the same age, and to have the same stage of disease. We showed supplementary table for full data compared non-PABC matching patient and non-PABC non-matching patient ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, available online). This study was approved by the Institutional Review Board of the Korea Cancer Center Hospital (IRB number: K-1512-002-044).

Statistical analyses
--------------------

Chi-square tests were used to compare clinical values between the PABC group and non-PABC group. Binary logistic regression analysis was performed to evaluate PABC risk factors. Statistical significance was set at *p*\<0.05. All statistical analyses were carried out using SPSS version 18.0 (SPSS Inc., Chicago, USA).

RESULTS
=======

Patient symptoms
----------------

Asymptomatic disease was observed less frequently in PABC patients than in non-PABC patients (4.3% of PABC patients versus 9.1% of non-PABC patients). A lump was the most commonly reported symptom in both patients groups ([Table 1](#T1){ref-type="table"}).

Patient characteristics and overall survival
--------------------------------------------

A total of 1,012 patients were analyzed in this study. The clinicopathological characteristics of PABC patients and non-PABC patients are shown in [Table 2](#T2){ref-type="table"}. The mean age was 33.7±4.3 years for PABC patients and 34.2±4.4 years for non-PABC patients (*p*=0.134). Because of our matching method, no significant difference in initial stage was noted between the PABC and non-PABC groups (*p*=0.121). However, the 10-year overall survival rate of PABC patients was worse than that of non-PABC patients (76.4% for PABC and 85.1% for non-PABC, *p*=0.011). The overall survival rates of PABC and non-PABC patients are shown in [Figure 2](#F2){ref-type="fig"}. The median follow-up period was 84.9 months (range, 1--216 months). Compared with non-PABC patients, a significantly larger proportion of PABC patients were diagnosed with histologic grade 3 breast cancer. In addition, PABC patients were more likely to have hormone receptor negative cancer compared with non-PABC patients. In a multivariate analysis, hormone receptor negativity was associated with poor overall survival (hazard ratio \[HR\], 2.249; 95% confidence interval \[CI\], 1.403--3.605; *p*=0.001). Histologic grade 3 did not show a statistically significant association with overall survival (HR, 1.026; 95% CI, 0.648--1.626; *p*=0.912).

[Table 3](#T3){ref-type="table"} shows the differences in characteristics between PABC patients and non-PABC patients. The PABC patients were more likely to be overweight (≥23.0 kg/m^2^), have an early age at menarche (≤13 years), and have a late age at first delivery (≥30 years). Multivariate analysis showed that late age at first delivery (odds ratio \[OR\], 2.446; 95% CI, 1.722--3.473; *p*\<0.001), early age at menarche (OR, 2.165; 95% CI, 1.566--2.994; *p*\<0.001), and overweight (OR, 1.389; 95% CI, 1.007--1.917; *p*=0.045) were more associated with PABC than non-PABC ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

This study is the first nationwide analysis of women with PABC in Korea. The overall survival rate was worse for the PABC group than for the non-PABC group. Symptomatic disease was more frequent in the PABC group. For both groups, a lump was the most commonly reported symptom. The following factors were significantly and independently associated with PABC (as compared with non-PABC): early age at menarche (≤13 years), late age at first delivery (≥30 years), and overweight (BMI ≥23.0 kg/m^2^). This study compared PABC patients and matched non-PABC patients. The number of non-PABC patients was higher than that of PABC patients. We used the matching method to analyze the characteristics of PABC and non-PABC in a comparative manner.

The poor overall survival rate that we observed among PABC patients is consistent with other studies \[[@B3][@B4]\]. In a study that compared risk factors between PABC patients and age-matched non-PABC patients, the following variables were significantly associated with the overall survival of patients with PABC: stage (stage III vs. stage I; HR, 5.25; 95% CI, 4.15--6.63; *p*\<0.001), surgery type (modified total mastectomy vs. breast conserving surgery; HR, 1.17; 95% CI, 1.05--1.30; *p*=0.005), and negative status of hormone receptor (estrogen receptor negative and progesterone receptor negative) (HR, 1.20; 95% CI, 1.07--1.36; *p*=0.003). This study also showed that, among patients with localized stages of breast cancer, PABC is a significant risk factor for worse survival after controlling for several factors, such as surgery type, age, race, and hormone receptor status (*p*=0.049) \[[@B9]\]. In our study, the overall survival rate was poorer for PABC than non-PABC after applying the 1:2 matching method. This result may be attributable to PABC patients having cancers with worse biological features, such as negative status of hormone receptor. Furthermore, we studied the factors associated with PABC.

When women become pregnant, various physiological changes occur in the breast, including engorgement, hypertrophy, and nipple discharge. These changes can obscure the symptoms of breast cancer during pregnancy and confuse physicians \[[@B10]\], which may explain the low frequency of symptomatic patients in the PABC group.

Because PABC has not been investigated thoroughly, no generally accepted risk factors have been established for this disease \[[@B10]\]. In a recent study, Strasser-Weippl et al. \[[@B11]\] compared the characteristics between PABC patients and non-PABC patients. They showed that the age at first gestation was higher in PABC patients than in non-PABC patients (≥30 years, PABC 30.3% vs. non-PABC 10.8%, *p*\<0.001). This result is consistent with our own finding that late age at delivery is more associated with PABC than with non-PABC. Moreover, we also found that early age at menarche and obesity were more associated with PABC than with non-PABC.

Compared with non-PABC patients, the higher rate of overweight among PABC patients may have resulted from the weight gain during pregnancy. To confirm whether rates of being overweight are truly higher in patients with PABC than those with non-PABC, future studies will need to investigate patient weights before pregnancy. This information is not part of the KBCS Registry database.

Our study had some limitations. First, disease-free survival rates and pregnancy outcomes could not be analyzed. However, the overall survival rate is an acceptable and powerful end-point in oncology. Although we did not investigate the disease-free survival rate or pregnancy outcomes, we believe that analyzing these factors would not change the power of our study. Second, like many other large databases, the KBCS Registry is missing some data.

In conclusion, our analysis shows that the following clinicopathological characteristics were more associated with PABC than with non-PABC: early age at menarche, late age at first childbirth, and BMI ≥23 kg/m^2^. Based on our results, future studies can identify risk factors for PABC by comparing PABC patients with healthy individuals. Such studies could contribute to improving survival by allowing early detection of PABC.
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SUPPLEMENTARY MATERIAL
======================

###### Supplementary Table 1

Clinicopathologic characteristics of matching patients and non-matching patients in non-PABC

![Flow chart of patient selection.\
KBCR=Korean Breast Cancer Society Registry; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; DCIS=ductal carcinoma in situ; PABC=pregnancy-associated breast cancer.](jbc-20-264-g001){#F1}

![Kaplan-Meier analysis of overall survival rates for pregnancy-associated breast cancer (PABC) patients and non-PABC patients (10-year overall survival rate: PABC, 76.4%; non-PABC, 85.1%; *p*=0.011).](jbc-20-264-g002){#F2}

###### Patient-reported symptoms at diagnosis

![](jbc-20-264-i001)

  -----------------------------------------------------------
  Symptom             PABC (n = 344)\   Non-PABC (n = 668)\
                      No. (%)           No. (%)
  ------------------- ----------------- ---------------------
  Asymptomatic        14 (4.3)          54 (9.1)

  Lump                283 (86.3)        510 (86.0)

  Pain                24 (7.3)          23 (3.9)

  Nipple discharge    30 (9.1)          29 (4.9)

  Skin change         8 (2.4)           7 (1.2)

  Nipple retraction   17 (5.2)          12 (2.0)

  Axillary mass       16 (4.9)          19 (3.2)
  -----------------------------------------------------------

PABC=pregnancy-associated breast cancer.

###### Clinicopathological characteristics of PABC patients and non-PABC patients

![](jbc-20-264-i002)

  Characteristic       PABC (n = 344) No. (%)   Non-PABC (n = 668) No. (%)   *p*-value          Characteristic   PABC (n = 344) No. (%)   Non-PABC (n = 668) No. (%)   *p*-value
  -------------------- ------------------------ ---------------------------- ------------------ ---------------- ------------------------ ---------------------------- -----------
  Age (yr)^\*^         33.7 ± 4.3               34.2 ± 4.4                   0.134              Nuclear grade                                                          \< 0.001
  Breast operation                                                           0.946               1               12 (3.5)                 45 (6.7)                     
   BCS                 149 (43.3)               301 (45.1)                    2                 73 (21.2)        193 (28.9)                                            
   Total mastectomy    180 (52.3)               357 (53.4)                    3                 156 (45.4)       215 (32.2)                                            
   Biopsy only         15 (4.4)                 8 (1.2)                       Unknown           103 (29.9)       215 (32.2)                                            
   Unknown             0                        2 (0.3)                      Hormone receptor                                             \< 0.001                     
  Axillary operation                                                         0.068               Positive        136 (39.5)               358 (53.6)                   
   SLNB                41 (11.9)                72 (10.8)                     Negative          172 (50.0)       241 (36.1)                                            
   ALND                276 (80.2)               566 (84.7)                    Unknown           36 (10.5)        69 (10.3)                                             
   No operation        27 (7.9)                 30 (4.5)                     HER2 status                                                  0.520                        
  T stage                                                                    0.251               Positive        69 (20.1)                129 (19.3)                   
   T0                  13 (3.8)                 18 (2.7)                      Negative          177 (51.5)       331 (49.6)                                            
   T1                  83 (24.1)                179 (26.8)                    Unknown           98 (28.4)        208 (21.2)                                            
   T2                  155 (45.1)               327 (49.0)                   Chemotherapy                                                 1.000                        
   T3                  66 (19.2)                104 (15.6)                    Yes               289 (84.0)       530 (79.3)                                            
   T4                  25 (7.3)                 36 (5.4)                      No                34 (9.9)         64 (9.6)                                              
   Unknown             2 (0.6)                  4 (0.6)                       Unknown           21 (6.1)         74 (11.1)                                             
  N stage                                                                    0.827              Radiotherapy                                                           0.178
   N0                  165 (48.0)               339 (50.7)                    Yes                                                                                      
   N1                  97 (28.2)                183 (27.4)                     Post-BCS         114 (33.1)       247 (37.0)                                            
   N2                  45 (13.1)                77 (11.5)                      PMRT             62 (18.0)        115 (17.2)                                            
   N3                  31 (9.0)                 64 (9.6)                       Palliative       2 (0.6)          1 (0.1)                                               
   Unknown             6 (1.7)                  5 (0.7)                       No                124 (36.0)       198 (29.6)                                            
  Stage                                                                      0.123               Unknown         42 (12.2)                107 (16.0)                   
   0                   13 (3.8)                 18 (2.7)                     Hormone therapy                                              \< 0.001                     
   I                   62 (18.0)                144 (21.6)                    Yes               123 (35.8)       306 (45.8)                                            
   II                  154 (44.8)               318 (47.6)                    No                164 (47.7)       231 (34.6)                                            
   III                 95 (27.6)                167 (25.0)                    Unknown           57 (16.6)        131 (19.6)                                            
   IV                  20 (5.8)                 21 (3.1)                                                                                                               
  Histologic grade                                                           \< 0.001                                                                                  
   1                   10 (2.9)                 55 (8.2)                                                                                                               
   2                   94 (27.3)                221 (33.1)                                                                                                             
   3                   170 (49.4)               249 (37.3)                                                                                                             
   Unknown             70 (20.4)                143 (21.4)                                                                                                             

PABC=pregnancy-associated breast cancer; BCS=breast-conserving surgery; SLNB=sentinel lymph node biopsy; ALND=axillary lymph node dissection; HER2=human epidermal growth factor receptor 2; Post-BCS=post-breast conserving surgery radiotherapy; PMRT=post-mastectomy radiotherapy.

^\*^Mean±SD.

###### Univariate analysis of characteristics of PABC compared with non-PABC

![](jbc-20-264-i003)

  Characteristic                           OR (95% CI)            *p*-value
  ---------------------------------------- ---------------------- -----------
  BMI ( ≥ 23 kg/m^2^ vs. \< 23 kg/m^2^)    1.427 (1.086--1.876)   0.011
  Oral pill (yes vs. no)                   1.265 (0.767--2.086)   0.356
  Family history (yes vs. no)              1.431 (0.921--2.225)   0.111
  First delivery ( ≥ 30 yr vs. \< 30 yr)   2.655 (1.902--3.707)   \< 0.001
  Menarche ( \< 13 yr vs. ≥ 13 yr)         1.762 (1.322--2.348)   \< 0.001

PABC=pregnancy-associated breast cancer; OR=odds ratio; CI=confidence interval; BMI=body mass index.

###### Multivariate analysis of characteristics of PABC compared with non-PABC

![](jbc-20-264-i004)

  Characteristic                           OR (95% CI)           *p*-value
  ---------------------------------------- --------------------- -----------
  BMI ( ≥ 23 kg/m^2^ vs. \< 23 kg/m^2^)    1.389 (1.007−1.917)   0.045
  First delivery ( ≥ 30 yr vs. \< 30 yr)   2.446 (1.722−3.473)   \< 0.001
  Menarche ( \< 13 yr vs. ≥ 13 yr)         2.165 (1.566−2.994)   \< 0.001

PABC=pregnancy-associated breast cancer; OR=odds ratio; CI=confidence interval; BMI=body mass index.
